Since sepsis is one of the leading causes of death in the intensive care units worldwide, much effort has been put to develop therapeutic agents blocking TLR activation, especially TLR2 and TLR4, although none has yet been clinically successful (see Section Toll-Like Receptor Antagonists/Inhibitors and Their Clinical Applications). This evidence concerns the gene TLR4 and Sepsis.